Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced Apoptosis
CNS Neuroscience & Therapeutics · 2024
DOI: 10.1111/cns.70124 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2024. Verfasst von Yida Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Glioblastoma, Phthalazines, Piperazines, DNA Damage. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Capital Funds for Health Improvement and Research, Beijing Municipal Health Commission.
Abstract (Originalsprache)
Aims
Patients with glioblastoma multiforme (GBM) do not benefit from current cancer treatments, and their prognosis is dismal. This study aimed to investigate the potential synergistic effects of TS‐2021, a third‐generation oncolytic adenovirus, combined with the PARP inhibitor olaparib in GBM.
Methods
TS‐2021’s impact on p66shc‐induced apoptosis, DNA damage response, and poly (ADP‐ribose) polymerase (PARP) activation was evaluated in GBM cells. The synergistic effect of TS‐2021 and olaparib was examined in GBM cell lines and an immunocompetent mouse model of GBM. Mechanistic studies focused on the role of p66shc phosphorylation in the observed effects.
Results
TS‐2021 triggered p66shc‐induced apoptosis, DNA damage response, and PARP activation. The combination of TS‐2021 and olaparib synergistically increased cell apoptosis and DNA damage and reduced PARP expression compared to monotherapy. Olaparib promoted TS‐2021 replication and release in GBM cells. Mechanistically, olaparib combined with TS‐2021 upregulated p66shc phosphorylation, enhancing tumor cell apoptosis. In vivo, the combination therapy inhibited tumor growth and prolonged survival, confirming the synergistic effect.
Conclusion
This study is the first to suggest that TS‐2021 sensitizes GBM cells with wild‐type BRCA1/2 to olaparib. The combination of TS‐2021 and olaparib shows a synergistic therapeutic effect against GBM, providing a promising treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain Tumor Research Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
- Department of Neurosurgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, China.
- Beijing Laboratory of Biomedical Materials, Beijing, China.
ORCID-Profile: Fusheng Liu
Förderung
- National Natural Science Foundation of China
- Capital Funds for Health Improvement and Research
- Beijing Municipal Health Commission
Zitieren
APA
Liu, Y., Fang, S., Wang, P., Zhang, J., & Liu, F. (2024). Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced Apoptosis. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70124
Vancouver
Liu Y, Fang S, Wang P, Zhang J, Liu F. Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced Apoptosis. CNS Neuroscience & Therapeutics. 2024. doi:10.1111/cns.70124
BibTeX
@article{Liu2024,
author = {Liu, Yida and Fang, Sheng and Wang, Peiwen and Zhang, Junwen and Liu, Fusheng},
title = {Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced Apoptosis},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
doi = {10.1111/cns.70124}
}
EUVIMED